| 000 | 01811 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516023317.0 | ||
| 264 | 0 | _c20151214 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1542-6270 | ||
| 024 | 7 |
_a10.1345/aph.1P391 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMease, Philip J | |
| 245 | 0 | 0 |
_aEpidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. _h[electronic resource] |
| 260 |
_bThe Annals of pharmacotherapy _cFeb 2011 |
||
| 300 |
_a179-88 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenergic Uptake Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmitriptyline _xadverse effects |
| 650 | 0 | 4 |
_aAntidepressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xchemically induced |
| 650 | 0 | 4 |
_aCyclopropanes _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Failure _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMilnacipran |
| 650 | 0 | 4 |
_aMyocardial Infarction _xchemically induced |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aSelective Serotonin Reuptake Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aStroke _xchemically induced |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aVenlafaxine Hydrochloride _xtherapeutic use |
| 700 | 1 | _aZimetbaum, Peter J | |
| 700 | 1 | _aDuh, Mei Sheng | |
| 700 | 1 | _aVekeman, Francis | |
| 700 | 1 | _aGuérin, Annie | |
| 700 | 1 | _aBoerstoel-Streefland, Mariette | |
| 700 | 1 | _aJiang, Wenjun | |
| 700 | 1 | _aLefebvre, Patrick | |
| 773 | 0 |
_tThe Annals of pharmacotherapy _gvol. 45 _gno. 2 _gp. 179-88 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1345/aph.1P391 _zAvailable from publisher's website |
| 999 |
_c20582123 _d20582123 |
||